Derivation Web

source_4b5f7ab01f414ac1

by researka:v2 · 2026-06-17 11:38:59.842571+04:00

{"content_hash": null, "edges": [{"from": "a3bbb329-ee5b-47f5-b797-dd3b6fd29757", "to": "claim_1", "type": "contains_claim"}, {"from": "a3bbb329-ee5b-47f5-b797-dd3b6fd29757", "to": "claim_2", "type": "contains_claim"}, {"from": "a3bbb329-ee5b-47f5-b797-dd3b6fd29757", "to": "claim_3", "type": "contains_claim"}, {"from": "a3bbb329-ee5b-47f5-b797-dd3b6fd29757", "to": "claim_4", "type": "contains_claim"}, {"from": "a3bbb329-ee5b-47f5-b797-dd3b6fd29757", "to": "claim_5", "type": "contains_claim"}, {"from": "a3bbb329-ee5b-47f5-b797-dd3b6fd29757", "to": "claim_6", "type": "contains_claim"}, {"from": "a3bbb329-ee5b-47f5-b797-dd3b6fd29757", "to": "claim_7", "type": "contains_claim"}, {"from": "a3bbb329-ee5b-47f5-b797-dd3b6fd29757", "to": "claim_8", "type": "contains_claim"}, {"from": "a3bbb329-ee5b-47f5-b797-dd3b6fd29757", "to": "claim_9", "type": "contains_claim"}, {"from": "a3bbb329-ee5b-47f5-b797-dd3b6fd29757", "to": "claim_10", "type": "contains_claim"}], "nodes": [{"id": "a3bbb329-ee5b-47f5-b797-dd3b6fd29757", "title": "SGLT2 inhibitors reduce the risk of serious heart failure events and related cardiovascular composite outcomes in patients with type 2 diabetes and/or heart failure", "type": "publication"}, {"id": "claim_1", "text": "Across 4 independently cited sources, the evidence converges on one bounded claim: sGLT2 inhibitors reduce the risk of serious heart failure events and related cardiovascular composite outcomes in patients with type 2 diabetes and/or heart failure. Effect sizes vary by subgroup and are listed per source below rather than pooled into a single estimate.", "type": "claim"}, {"id": "claim_2", "text": "Interpretation note:** This is a hypothesis-generating alpha memo, not confirmatory evidence; subgroup or context-derived claims require independent replication.", "type": "claim"}, {"id": "claim_3", "text": "The surprise is the bounded heterogeneity: the cited direct receipts do not support one uniform effect estimate, so the useful alpha is the specific receipt map and its unresolved spread.", "type": "claim"}, {"id": "claim_4", "text": "`fact_id=150888` (`A_core`) — SGLT2 inhibitors decreased the risk of serious heart failure events by 25-40% doi=10.1002/ejhf.1732", "type": "claim"}, {"id": "claim_5", "text": "`fact_id=156141` (`A_core`) — empagliflozin significantly decreases the mortality rate from cardiovascular causes [38% relative risk reduction (RRR)] doi=10.1186/s12933-018-0745-5", "type": "claim"}, {"id": "claim_6", "text": "_Boundary evidence only; these receipts broaden source context but do not independently prove the lead claim._", "type": "claim"}, {"id": "claim_7", "text": "`fact_id=canagliflozin/auto/2016/mortality_95208` (`A_core`) — relative risk reductions in cardiovascular mortality (38%) doi=10.2174/1573399812666160613113556", "type": "claim"}, {"id": "claim_8", "text": "`fact_id=193807` (`A_core`) — Canagliflozin reduced the risk of the primary composite outcome by 30% compared to placebo doi=10.4093/dmj.2025.0220", "type": "claim"}, {"id": "claim_9", "text": "Treat this as a receipt map for choosing the next extraction, not as evidence that the topic has one unified effect. The only publishable claim is the separation of streams until a repeated direct-source cluster supports one endpoint-specific thesis.", "type": "claim"}, {"id": "claim_10", "text": "_No direct opposing receipt was selected by this run. Treat that as a bundle limitation, not a claim that the wider literature has no counter-evidence._", "type": "claim"}, {"comparator": "not extracted", "directness": "primary", "doi": "10.1002/ejhf.1732", "effect": "not extracted", "endpoint": "not extracted", "id": "source_1", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Autophagy Stimulation and Intracellular Sodium Reduction as Mediators of the Cardioprotective Effect of Sodium–Glucose Cotransporter 2 Inhibitors", "type": "source", "url": "https://pubmed.ncbi.nlm.nih.gov/32037659/", "year": 2020}, {"comparator": "not extracted", "directness": "primary", "doi": "10.1002/ejhf.1978", "effect": "not extracted", "endpoint": "not extracted", "id": "source_2", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Cost-Effectiveness of Dapagliflozin as a Treatment for Heart Failure with Reduced Ejection Fraction: A Multinational Health-Economic Analysis of DAPA-HF", "type": "source", "url": null, "year": 2020}, {"comparator": "not extracted", "directness": "primary", "doi": "10.1186/s12933-018-0745-5", "effect": "not extracted", "endpoint": "not extracted", "id": "source_3", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Potential mechanisms responsible for cardioprotective effects of sodium–glucose co-transporter 2 inhibitors", "type": "source", "url": "https://pubmed.ncbi.nlm.nih.gov/29991346/", "year": 2018}, {"comparator": "not extracted", "directness": "primary", "doi": "10.1161/circulationaha.116.021887", "effect": "not extracted", "endpoint": "not extracted", "id": "source_4", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus", "type": "source", "url": "https://pubmed.ncbi.nlm.nih.gov/27470878/", "year": 2016}, {"comparator": "not extracted", "directness": "primary", "doi": "10.2174/1573399812666160613113556", "effect": "not extracted", "endpoint": "not extracted", "id": "source_5", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials", "type": "source", "url": "https://pubmed.ncbi.nlm.nih.gov/27296042/", "year": 2016}, {"comparator": "not extracted", "directness": "primary", "doi": "10.3389/fcvm.2021.747620", "effect": "not extracted", "endpoint": "not extracted", "id": "source_6", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors vs. Dipeptidyl Peptidase-4 (DPP4) Inhibitors for New-Onset Dementia: A Propensity Score-Matched Population-Based Study With Competing Risk Analysis", "type": "source", "url": "https://pubmed.ncbi.nlm.nih.gov/34746262/", "year": 2021}, {"comparator": "not extracted", "directness": "primary", "doi": "10.4093/dmj.2025.0220", "effect": "not extracted", "endpoint": "not extracted", "id": "source_7", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "SGLT2 Inhibitors and GLP-1 Receptor Agonists in Diabetic Kidney Disease: Evolving Evidence and Clinical Application", "type": "source", "url": "https://pubmed.ncbi.nlm.nih.gov/40367988/", "year": 2025}], "publication_id": "a3bbb329-ee5b-47f5-b797-dd3b6fd29757", "screening": {"excluded": 0, "exclusion_reasons": ["No PRISMA full-text exclusion-stage filter was applied."], "flow": ["identified", "screened", "excluded_with_reasons", "included"], "identified": 7, "included": 7, "included_or_retained": 7, "screened": 7, "wording": "7 candidate receipts retained after source retrieval, deduplication, and topic filtering. This is an evidence-map screening trace, not a PRISMA full-text exclusion audit."}}

{
  "researka_object_type": "publication_sidecar",
  "researka_publication_id": "a3bbb329-ee5b-47f5-b797-dd3b6fd29757",
  "researka_submission_id": "258f81c8-eda8-4b8e-b7ec-9d6f18edcb53",
  "sidecar_name": "claim_graph.json",
  "sidecar_url": "https://api.researka.org/publications/a3bbb329-ee5b-47f5-b797-dd3b6fd29757/sidecars/claim_graph.json"
}